NCT04318743View on ClinicalTrials.gov

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

June 10, 2021

Study Completion Date

June 10, 2021

Conditions
Healthy
Interventions
DRUG

Glepaglutide

GLP-2

Trial Locations (1)

9728

PRA Health Sciences- Location Martini, Groningen

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
lead

Zealand Pharma

INDUSTRY

NCT04318743 - A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector. | Biotech Hunter | Biotech Hunter